CN115039759A - Erythrocyte preservation solution and application thereof - Google Patents
Erythrocyte preservation solution and application thereof Download PDFInfo
- Publication number
- CN115039759A CN115039759A CN202210215718.7A CN202210215718A CN115039759A CN 115039759 A CN115039759 A CN 115039759A CN 202210215718 A CN202210215718 A CN 202210215718A CN 115039759 A CN115039759 A CN 115039759A
- Authority
- CN
- China
- Prior art keywords
- erythrocytes
- erythrocyte
- preservation
- preservation solution
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003743 erythrocyte Anatomy 0.000 title claims abstract description 145
- 239000003761 preservation solution Substances 0.000 title claims abstract description 59
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 44
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229940116269 uric acid Drugs 0.000 claims abstract description 42
- 238000004321 preservation Methods 0.000 claims abstract description 29
- 239000000243 solution Substances 0.000 claims abstract description 16
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 11
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 11
- 238000000338 in vitro Methods 0.000 claims abstract description 10
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 230000002587 anti-hemolytic effect Effects 0.000 abstract description 4
- 230000002035 prolonged effect Effects 0.000 abstract description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 17
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 8
- 229930003268 Vitamin C Natural products 0.000 description 8
- 235000019154 vitamin C Nutrition 0.000 description 8
- 239000011718 vitamin C Substances 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 3
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 3
- 108010093894 Xanthine oxidase Proteins 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000003617 erythrocyte membrane Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000006909 anti-apoptosis Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- PJAHUDTUZRZBKM-UHFFFAOYSA-K potassium citrate monohydrate Chemical compound O.[K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PJAHUDTUZRZBKM-UHFFFAOYSA-K 0.000 description 1
- 229940050931 potassium citrate monohydrate Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention provides a red blood cell preservation solution and application thereof. The erythrocyte preservation solution comprises erythrocyte preservation base solution and antioxidant, and the antioxidant comprises uric acid. The erythrocyte preservation solution can be used for preserving erythrocytes in vitro for a long time, and uric acid is introduced into the erythrocyte preservation base solution to serve as an antioxidant, so that the erythrocytes can be further activated, the anti-hemolytic apoptosis capacity of the erythrocytes is remarkably enhanced, the in vitro preservation time is obviously prolonged, and the erythrocyte preservation solution has great application value for the ultra-long-term in vitro low-temperature preservation of erythrocytes for blood transfusion.
Description
Technical Field
The invention belongs to the technical field of medical treatment, and particularly relates to a red blood cell preservation solution and application thereof.
Background
Red Blood Cell (RBC) is the main component of human blood, and the RBC content in adult blood reaches 5 × 10 12 /L(5×10 9 5000million/mL), hematocrit (the percentage of the volume of red blood cells in whole blood) of 40-50%. Principal generation of red blood cellsThe physiological function is to transport oxygen from the lungs and release it to the body for metabolism. Under the emergency conditions of blood loss, anemia and the like, the number of red blood cells of the body is seriously reduced, and the life safety is threatened. Therefore, erythrocyte transfusion has become the basic treatment means for clinically critical patients. At present, the red blood cells for transfusion and emergency treatment are mainly from social donation, and then are separated by the red blood cells and stored in a red blood cell preservation solution. However, when blood is stored in a liquid medium, a series of biochemical and structural changes of red blood cells occur, namely damage to red blood cell storage, which affects survival of red blood cells after transfusion and causes functional changes thereof. At present, the development of a preservation solution for red blood cells has become a focus and hot spot for research of numerous scholars.
CN1857312A discloses a cryoprotectant for erythrocytes, which comprises small molecular sugar (trehalose, glucose, sucrose, maltose, fructose or mannitol), sodium chloride, potassium dihydrogen phosphate and disodium hydrogen phosphate. The protective solution can realize cryopreservation of erythrocytes, reduce the hemolysis rate of erythrocytes, and greatly simplify the washing procedure of the erythrocytes after thawing, but the preservation time of the protective solution on the erythrocytes needs to be further improved.
CN111919835A discloses a preservation solution for maintaining the activity of red blood cells, comprising: heparin-poloxamer, glycine, potassium dihydrogen phosphate, basic fibroblast growth factor and trimethoprim can ensure the oxygen carrying activity of the red blood cells, but the preservation solution only maintains the activity of the red blood cells by increasing the effective concentration of nitric oxide gas, and the research on the apoptosis and hemolysis of the red blood cells is not disclosed.
CN104705287A discloses a frozen preservation solution for red blood cells, which comprises: potassium citrate monohydrate, sodium dihydrogen phosphate dihydrate, disodium hydrogen phosphate dodecahydrate and glycerol. The preservation solution can realize physiological balance inside and outside the erythrocyte membrane, avoids rupture of the erythrocyte membrane, but the existence of glycerol can lead to the washing process of the later erythrocyte during use to be complicated, and causes burden to medical personnel.
Based on the above research, it can be seen that many developments are currently made for erythrocyte preservation solutions, and although the lifetime of erythrocytes can be obviously prolonged, the key core technology of anti-apoptosis and anti-hemolysis of erythrocytes is still not known, and research needs to be made for further improving the anti-apoptosis, anti-hemolysis and anti-natural disintegration capability of erythrocyte preservation solutions on erythrocytes and prolonging the preservation time of erythrocytes.
Disclosure of Invention
Aiming at the defects of the prior art and the practical requirements, the invention aims to provide a red blood cell preservation solution and application thereof. The erythrocyte preservation solution can strongly protect erythrocytes and extremely remarkably prolong the service life of erythrocytes.
In order to achieve the purpose, the invention adopts the following technical scheme:
in a first aspect, the invention provides a red blood cell preservation solution, which comprises a red blood cell preservation base solution and an antioxidant, wherein the antioxidant comprises uric acid.
In the invention, uric acid is introduced into the erythrocyte preservation base fluid as an antioxidant, so that erythrocytes can be further activated, the anti-hemolytic apoptosis capacity of erythrocytes is remarkably enhanced, the in vitro preservation time is obviously prolonged, and the erythrocyte preservation base fluid has great application value for the ultra-long-term in vitro low-temperature preservation of erythrocytes for blood transfusion.
It should be noted that liver Xanthine Dehydrogenase (XDH) is a rate-limiting enzyme for uric acid production, and the absence of XDH enzyme in erythrocytes means that, even when adenine (a precursor of uric acid production) is added to conventional erythrocyte storage solutions, uric acid cannot be efficiently produced by erythrocytes. Therefore, red blood cells themselves cannot store sufficient levels of uric acid unless added extracellularly. Uric acid is a purine metabolite specific to primates (humans, etc.). In other mammals, uric acid is further metabolized to allantoin, which is excreted in the urine. Research has proved that uric acid as antioxidant can effectively improve the life of model organism, so uric acid is not only end product of metabolism in human body, but also has important physiological function.
In the present invention, the base fluid for erythrocyte preservation may be a commercially available erythrocyte preservation fluid (including MAP preparations and Ashwage's solution).
Wherein the MAP preparation contains trisodium citrate, citric acid, glucose, sodium dihydrogen phosphate, adenine, sodium chloride and mannitol.
The Ashi solution contains sodium chloride, sodium citrate, citric acid and glucose.
In the invention, the concentration of the uric acid in the erythrocyte preservation solution is 10-1000 mu M.
The concentration of the above-mentioned carrier is 10 to 1000. mu.M, and may be 10. mu.M, 50. mu.M, 100. mu.M, 200. mu.M, 300. mu.M, 400. mu.M, 500. mu.M, 600. mu.M, 700. mu.M, 800. mu.M, 900. mu.M, 1000. mu.M, or the like.
Other point values within the above range can be selected, and are not described in detail herein.
Preferably, the concentration of the uric acid in the erythrocyte preservation solution is 200-800 μ M.
Further preferably, the concentration of the uric acid in the erythrocyte preservation solution is 300-500 mu M.
The concentration of the uric acid in the erythrocyte preservation solution is 10-1000 mu M, which can ensure the protection effect on the erythrocytes, preferably 200-800 mu M, and more preferably 300-500 mu M, because the normal value of the uric acid level in a human body is 300 mu M at 100-300 mu M, and the hyperuricemia can reach 500 mu M. In addition, according to the in vitro erythrocyte culture experiment of the inventor, 300-500 mu M uric acid can remarkably protect erythrocytes and resist the hemolysis induced by vitamin C. In addition, even if vitamin C is not contained, the red blood cells can be naturally hemolyzed in the MAP nutrient solution, and the addition of uric acid can obviously protect the red blood cells and resist natural hemolysis reaction.
In the invention, the use temperature of the erythrocyte preservation solution is 4-10 ℃.
The temperature of 4-10 deg.C can be 4 deg.C, 4.5 deg.C, 5 deg.C, 5.5 deg.C, 6 deg.C, 6.5 deg.C, 7 deg.C, 7.5 deg.C, 8 deg.C, 8.5 deg.C, 9 deg.C, 9.5 deg.C or 10 deg.C.
Other values within the above range can be selected, and are not further described herein.
In a second aspect, the invention provides a use of the red blood cell preservation solution according to the first aspect for preserving red blood cells in vitro.
Compared with the prior art, the invention has the following beneficial effects:
in the invention, uric acid is introduced into the erythrocyte preservation base solution as an antioxidant, so that erythrocytes can be activated, the anti-hemolytic apoptosis capability of the erythrocytes is remarkably enhanced, and the membrane stability of the erythrocytes is improved, so that the erythrocytes are preserved for a long time in an optimal state, and the erythrocyte preservation base solution has great application value for the ultra-long-term in-vitro low-temperature preservation of erythrocytes for blood transfusion.
Drawings
FIG. 1 is a graph showing the results of preservation of erythrocytes by the erythrocyte preservation solution obtained in example 1;
FIG. 2 is a graph showing the results of preservation of erythrocytes by the erythrocyte preservation solution obtained in example 2;
FIG. 3 is a graph showing the results of preservation of erythrocytes in the erythrocyte preservation solution obtained in example 3;
FIG. 4 is a graph showing the results of preservation of erythrocytes in the erythrocyte preservation solution obtained in example 4;
FIG. 5 is a graph showing the results of preservation of erythrocytes by the erythrocyte preservation solution obtained in example 5;
FIG. 6 is a graph showing the results of preservation of erythrocytes in the erythrocyte preservation solution obtained in example 6;
FIG. 7 is a graph showing the results of preservation of erythrocytes by the erythrocyte preservation solution obtained in comparative example 1;
FIG. 8 is a graph of the hemolytic apoptosis of erythrocytes in different dosing groups.
Detailed Description
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitation of the present invention.
The following preparations, examples, comparative examples and test examples were obtained by purchasing the corresponding materials and raw materials as follows:
wherein the MAP reagent is purchased from Shanghai Yuanmu, and has a model number of R18099; ashi liquor purchased from Beijing Solaibao, model number R1016; uric acid is purchased from Shanghai leaf organism, and has a model number of S30640. The remaining materials and starting materials are not specifically described and are commercially available from other sources.
Example 1
The present embodiment provides a red blood cell preservation solution, including: 1mL of MAP reagent and 500. mu.M of uric acid.
Wherein, 500 mu M refers to the concentration of uric acid in the erythrocyte preservation solution.
Example 2
The present embodiment provides a red blood cell preservation solution, including: 1mL MAP reagent, 200. mu.M uric acid.
Wherein 200 mu M refers to the concentration of uric acid in the erythrocyte preservation solution.
Example 3
This example provides a preservation solution for red blood cells, which is different from example 1 only in that the concentration of uric acid in the preservation solution for red blood cells is 10 μ M, and the other parameters are consistent with example 1.
Example 4
This example provides a preservation solution for red blood cells, which is different from example 1 only in that the concentration of uric acid in the preservation solution for red blood cells is 50 μ M, and the other parameters are consistent with example 1.
Example 5
This example provides a preservation solution for red blood cells, which is different from example 1 only in that the concentration of uric acid in the preservation solution for red blood cells is 100 μ M, and the other parameters are consistent with example 1.
Example 6
This example provides a preservation solution for red blood cells, which is different from example 1 only in that the concentration of uric acid in the preservation solution for red blood cells is 1000. mu.M, and the other parameters are consistent with example 1.
Comparative example 1
This comparative example provides a red blood cell preservation solution, which differs from example 1 only in that the red blood cell preservation solution does not include uric acid, and the remaining parameters are consistent with example 1.
Test example 1
In this test example, erythrocytes were preserved with the erythrocyte preservation solutions obtained in examples 1 to 6 and comparative example 1, and the ability of erythrocytes to resist hemolytic apoptosis was observed.
The test method is as follows: adult peripheral blood (1 mL) was collected and red blood cells were counted. The cells were plated in 12-well plates according to the standard of 50 thousands RBC/1mL red blood cell preservation solution. Incubated at 37 ℃. After 24h observation was carried out under a microscope.
As shown in FIGS. 1 to 7, it can be seen from FIGS. 1 to 6 that a large number of RBCs are still in a non-hemolyzed state and the cells are bright after the preservation time of the red blood cells in the red blood cell preservation solution provided by the present invention is 24 hours. Whereas the erythrocytes in FIG. 7 (which were also preserved without uric acid) were substantially totally hemolyzed after 24h incubation at 37 ℃ with only the erythrocyte membrane structure remaining. By comparison, the specific protection effect of uric acid on erythrocytes can be fully shown.
Test example 2
In this test example, 100 ten thousand red blood cells were placed in 1640 medium in normoxic (21% O) conditions 2 ) And hypoxia (5% O) 2 ) Then, two-factor dosing experiments of 1mM Vitamin C (VC), 500. mu.M Uric Acid (UA) and 1mM VC + 500. mu.M UA were performed, a blank control group was set, and 3 days later, observation was performed under a microscope.
As shown in FIG. 8, 3 days after the administration of the drug, the hemolyzed apoptosis of erythrocytes in the 1mM VC group was significantly reduced, while the hemolyzed apoptosis of erythrocytes in the 500. mu.M UA group was significantly reduced, as compared with the control group (i.e., ctrl group). Especially at 5% O 2 Next, nearly 100% of erythrocytes are hemolyzed by VC, while at least more than 50% of erythrocytes have intact cell membrane structure under the protection of UA. It can be seen from the VC + UA group that UA can strongly protect erythrocytes against VC-induced hemolytic apoptosis.
In conclusion, the invention introduces uric acid as an antioxidant into the erythrocyte preservation base solution, can activate erythrocytes, remarkably enhance the anti-hemolytic apoptosis capacity of the erythrocytes, and further improve the membrane homeostasis of the erythrocytes, thereby realizing the long-term preservation of the erythrocytes in the optimal state, and the invention has great application value and wide application prospect for the ultra-long-term in-vitro low-temperature preservation of the erythrocytes for blood transfusion.
The applicant declares that the above description is only a specific embodiment of the present invention, but the scope of the present invention is not limited thereto, and it should be understood by those skilled in the art that any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope of the present invention are within the scope and disclosure of the present invention.
Claims (7)
1. The erythrocyte preservation solution is characterized by comprising erythrocyte preservation base solution and antioxidant;
the antioxidant comprises uric acid.
2. The red blood cell preservation solution according to claim 1, wherein the red blood cell preservation base solution comprises: MAP formulation or Ashi solution.
3. The erythrocyte preservation solution of claim 1 or 2, wherein the concentration of the uric acid in the erythrocyte preservation solution is 10 to 1000 μ M.
4. The erythrocyte preservation solution of any one of claims 1 to 3, wherein the concentration of the uric acid in the erythrocyte preservation solution is 200 μ M and 800 μ M.
5. An erythrocyte preservation solution as claimed in any one of claims 1 to 4, wherein the concentration of uric acid in the erythrocyte preservation solution is 300-500 μ M.
6. The erythrocyte preservation solution according to any one of claims 1 to 5, wherein the erythrocyte preservation solution is used at a temperature of 4 to 10 ℃.
7. Use of the red blood cell preservation solution of any one of claims 1-6 for preserving red blood cells in vitro.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210215718.7A CN115039759B (en) | 2022-03-07 | 2022-03-07 | Erythrocyte preservation solution and application thereof |
| PCT/CN2023/078627 WO2023169249A1 (en) | 2022-03-07 | 2023-02-28 | Red blood cell preservation solution and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210215718.7A CN115039759B (en) | 2022-03-07 | 2022-03-07 | Erythrocyte preservation solution and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115039759A true CN115039759A (en) | 2022-09-13 |
| CN115039759B CN115039759B (en) | 2023-11-03 |
Family
ID=83157282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210215718.7A Active CN115039759B (en) | 2022-03-07 | 2022-03-07 | Erythrocyte preservation solution and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115039759B (en) |
| WO (1) | WO2023169249A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023169249A1 (en) * | 2022-03-07 | 2023-09-14 | 细胞生态海河实验室 | Red blood cell preservation solution and use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987004072A1 (en) * | 1986-01-08 | 1987-07-16 | Shobhana Vora | Method and additives for improving the quality and shelf life of stored blood |
| CN113383769A (en) * | 2021-06-29 | 2021-09-14 | 广州朗坤生物科技有限公司 | Cell preservation solution and preparation method and application thereof |
| CN113557295A (en) * | 2019-03-15 | 2021-10-26 | 株式会社美加细胞 | Preservation solution for mammalian cells |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020120A (en) * | 1997-10-22 | 2000-02-01 | South Alabama Medical Science Foundation | Use of N-acetylcysteine to store red blood cells and a method of aging red cells with nitrogen |
| CN115039759B (en) * | 2022-03-07 | 2023-11-03 | 细胞生态海河实验室 | Erythrocyte preservation solution and application thereof |
-
2022
- 2022-03-07 CN CN202210215718.7A patent/CN115039759B/en active Active
-
2023
- 2023-02-28 WO PCT/CN2023/078627 patent/WO2023169249A1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987004072A1 (en) * | 1986-01-08 | 1987-07-16 | Shobhana Vora | Method and additives for improving the quality and shelf life of stored blood |
| CN113557295A (en) * | 2019-03-15 | 2021-10-26 | 株式会社美加细胞 | Preservation solution for mammalian cells |
| CN113383769A (en) * | 2021-06-29 | 2021-09-14 | 广州朗坤生物科技有限公司 | Cell preservation solution and preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| MANON BARDYN: "Restoration of Physiological Levels of Uric Acid and Ascorbic Acid Reroutes the Metabolism of Stored Red Blood Cells", 《METABOLITES》 * |
| VASSILIS L. TZOUNAKAS: "Uric acid variation among regular blood donors is indicative of red blood cell susceptibility to storage lesion markers: a new hypothesis tested", 《TRANSFUSION》 * |
| YUNXIAO SONG: "Uric Acid Provides Protective Role in Red Blood Cells by Antioxidant Defense: A Hypothetical Analysis", 《HINDAWI》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023169249A1 (en) * | 2022-03-07 | 2023-09-14 | 细胞生态海河实验室 | Red blood cell preservation solution and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023169249A1 (en) | 2023-09-14 |
| CN115039759B (en) | 2023-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huckabee | Relationship of pyruvate and lactate during anaerobic metabolism. V: Coronary adequacy | |
| JP5230042B2 (en) | Preservatives for animal cells or organs and methods for their preservation. | |
| Peterson et al. | Reactive oxygen species may cause myocardial reperfusion injury | |
| Opperdoes et al. | Trypanosoma brucei: an evaluation of salicylhydroxamic acid as a trypanocidal drug | |
| CN113016782B (en) | Cell preservation solution and preparation method and application thereof | |
| JPS63502107A (en) | Solution to stabilize red blood cells during storage | |
| Searcy et al. | Congenital hemolytic anemia in the Basenji dog due to erythrocyte pyruvate kinase deficiency | |
| CN112841174A (en) | Cryopreservation liquid for long-term storage of human umbilical cord mesenchymal stem cells | |
| US4703040A (en) | Treatment of adult respiratory distress syndrome (ARDS) using fructose diphosphate (FDP) | |
| Zabucchi et al. | Exocytosis in human polymorphonuclear leukocytes induced by A 23187 and calcium | |
| KR20070095956A (en) | Method of separating pancreatic islet | |
| Schrier et al. | The hemolytic effect of primaquine: IX. Enzymatic abnormalities in primaquine-sensitive erythrocytes | |
| WO2023169249A1 (en) | Red blood cell preservation solution and use thereof | |
| CN111513059B (en) | Erythrocyte preservation solution and application thereof | |
| Morshed et al. | Propylene glycol-mediated cell injury in a primary culture of human proximal tubule cells | |
| US4308257A (en) | Accelerating cellular repair composition for the human body and method of administering same | |
| Zhou et al. | Effects of coenzyme Q10 on myocardial protection during cardiac valve replacement and scavenging free radical activity in vitro | |
| Rubenberg et al. | Intravascular coagulation in a case of Clostridium perfringens septicaemia: treatment by exchange transfusion and heparin. | |
| Rothstein et al. | The relationship of fermentation to cell structure in yeast | |
| CN109122666B (en) | Ready-to-use erythrocyte cryoprotectant for resuscitation and use method | |
| Buttner et al. | A randomized comparison of crystalloid and blood-containing cardioplegic solutions in 60 patients. | |
| Truitt Jr et al. | Anesthesia. LII. Effects of Alcohols and Acetaldehyde on Oxidative Phosphorylation in Brain | |
| Tsan | Stimulation of the hexose monophosphate shunt independent of hydrogen peroxide and superoxide production in rabbit alveolar macrophages during phagocytosis | |
| CN109349270A (en) | Cell-preservation liquid and the method for saving cell using cell-preservation liquid | |
| Biaglow et al. | The enhanced radiation response of an in vitro tumour model by cyanide released from hydrolysed amygdalin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230106 Address after: 300462 2-1-101, Building 1-3, Bolong Industrial Park, north of Yuexin Road and east of Huixin Road, Binhai Science and Technology Park, Binhai New Area, Tianjin Applicant after: Cell Ecology Haihe Laboratory Applicant after: Hematology Hospital of Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) Address before: 300020 No. 288, Nanjing Road, Heping District, Tianjin Applicant before: Hematology Hospital of Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |